DRUG:AU:AU-BetaShares Global Healthcare Currency Hedged (AUD)

ETF | Others |

Last Closing

USD 7.705

Change

+0.19 (+2.46)%

Market Cap

USD 0.17B

Volume

0.10M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

NA

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-05-13 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
VAS:AU Vanguard Australian Shares

+0.55 (+0.54%)

USD 18.39B
IVV:AU iShares Core S&P 500 AUD

+1.23 (+2.07%)

USD 11.33B
VGS:AU Vanguard MSCI International Sh..

+2.00 (+1.48%)

USD 10.39B
QUAL:AU VanEck Vectors MSCI World ex A..

+1.06 (+1.90%)

USD 7.35B
IOZ:AU Ishares Core S&P/Asx 200

+0.19 (+0.57%)

USD 6.40B
VTS:AU Vanguard US Total Market Share..

+8.54 (+1.95%)

USD 5.71B
STW:AU SPDR® S&P/ASX 200 Fund

+0.42 (+0.56%)

USD 5.54B
NDQ:AU Betashares Nasdaq 100

+0.96 (+2.03%)

USD 5.22B
HNDQ:AU BetaShares NASDAQ 100 ETF - Cu..

+0.60 (+1.45%)

USD 4.86B
A200:AU BetaShares Australia 200

+0.77 (+0.56%)

USD 4.72B

ETFs Containing DRUG:AU

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -1.97% 23% F 49% F
Dividend Return 0.35% 10% F 6% D-
Total Return -1.62% 20% F 47% F
Trailing 12 Months  
Capital Gain -10.20% 8% B- 43% F
Dividend Return 2.92% 40% F 32% F
Total Return -7.28% 6% D- 44% F
Trailing 5 Years  
Capital Gain 18.17% 32% F 56% F
Dividend Return 11.22% 24% F 20% F
Total Return 29.40% 27% F 54% F
Average Annual (5 Year Horizon)  
Capital Gain 5.58% 61% D- 56% F
Dividend Return 7.49% 61% D- 56% F
Total Return 1.91% 54% F 38% F
Risk Return Profile  
Volatility (Standard Deviation) 8.34% 64% D 91% A-
Risk Adjusted Return 89.85% 82% B 94% A
Market Capitalization 0.17B 33% F 64% D

Annual Financials (AUD)

Quarterly Financials (AUD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.